Table 3.
Non randomized clinical trials of HCC treatment with SA monotherapy
|
Publication |
Type of study |
Number of enrolled patients and controls |
Type of Cancer |
SA used for treatment |
Response to treatment-outcome |
|
|---|---|---|---|---|---|---|
| Patients | Controls | |||||
| Dimitroulopoulos 2002
[211] |
NRCT |
15* |
13# |
Advanced HCC |
OCT LAR (20 to 30 mg/28d) |
↑S, ↑QoL |
| Gill 2005
[212] |
NRCT |
22* |
20# |
Advanced HCC |
OCT LAR (20 mg/28d) |
↑S, ↑QoL, ↓AFP, PR |
| Samonakis 2002
[213] |
NRCT |
32* |
27# |
Advanced HCC |
NS |
↑S, ↑QoL, |
| Plentz 2005
[214] |
NRCT |
41* |
33▪ |
Advanced HCC |
OCT LAR (30 mg/28d) |
=S |
| Schoniger-Hekele 2009
[215] |
NRCT |
25* |
39† |
Advanced HCC |
OCT LAR (30 mg/28d) |
↑S |
| |
|
or 17▪ |
|
|
|
|
| |
|
or 17▫ |
|
|
|
|
| Slijkhuis 2005 [216] | NRCT | 30* | - | Advanced HCC | OCT LAR (30 mg/28d) | SD |
NRCT, Non randomized clinical trial.
AFP, Alpha fetoprotein.
S, Survival.
TACE, Transarterial chemoembolization.
PR, Partial response.
SD, Stable disease.
NS, Not specified.
QoL, Quality of life.
*: treated patients.
#: untreated patients.
▪: TACE treatment.
▫: multimodal therapy.
†: palliative.